Sugi Predict

Sugi Predict / Compounds / SCHEMBL5381808

SCHEMBL5381808

SCHEMBL5381808

CN(C)C(=O)n1cnc(S(=O)(=O)CC23CC4CC(CC(C4)C2)C3)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ EPHX2 P34913 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ KAT8 Q9H7Z6 1/20 0.33
▸ SCN5A Q14524 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5384749 0.75 DPP4 (0.40) DPP4
SCHEMBL5381535 0.75 ALDH1A1 (0.36) DPP4ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL5376492 0.73 DPP4 (0.42) DPP4ALDH1A1KAT8SCN9ATSHR
SCHEMBL5376197 0.72 DPP4 (0.40) DPP4GAA
SCHEMBL5380486 0.70 DPP4 (0.42) DPP4
SCHEMBL5376966 0.70 DAGLA (0.43) DPP4KMT2AMEN1SMN1; SMN2TP53
SCHEMBL5381829 0.69 DPP4 (0.83) DPP4ALDH1A1KMT2A
SCHEMBL5381823 0.69 DPP4 (0.83) DPP4ALDH1A1KMT2A
SCHEMBL5376390 0.68 SCN4A (0.39) DPP4KMT2ASMN1; SMN2TP53
SCHEMBL5382766 0.68 DPP4 (0.44) DPP4ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 — — US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 — — US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 — — EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 — — EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 — — US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 — — US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885ALDH1A1 1026/4885KMT2A 2591/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885ALDH1A1 1026/4885KMT2A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.